Abstract
Purpose
The benefit of terminal blood cardioplegia (TWBCP) is insufficient after prolonged ischemia associated with inevitable oxidant-mediated injury by this modality alone. We tested the effects of TWBCP supplemented with high-dose olprinone, which is a phosphodiesterase III inhibitor, a clinically available compound with the potential to reduce oxidant stress and calcium overload. We evaluated the effects with respect to avoiding oxidant-mediated myocardial reperfusion injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in a infantile piglet cardiopulmonary bypass (CPB) model.
Methods
Fifteen piglets were subjected to 90 min of cardioplegic arrest on CPB, followed by 30 min of reperfusion. In group I, uncontrolled reperfusion was applied without receiving TWBCP; in group II, TWBCP was given; in group III, TWBCP was supplemented with olprinone (3 μg/ml). Myocardial performance was evaluated before and after CPB by a left ventricular (LV) function curve and pressure-volume loop analyses. Biochemical injury was determined by measurements of troponin-T and lipid peroxide (LPO) in coronary sinus blood.
Results
Group III showed significant LV performance recovery (group I, 26.5% ± 5.1%; group II, 42.9% ± 10.8%; group III, 81.9% ± 24.5%, P < 0.01 vs. groups I and II), associated with significant reduction of troponin-T and LPO at the reperfusion phase. No piglets in group III needed electrical cardioversion.
Conclusion
We concluded that TWBCP with olprinone reduces myocardial reperfusion injury by reducing oxidant-mediated lipid peroxidation, and it accelerates prompt and persistent LV functional recovery with suppression of reperfusion arrhythmia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jonas RA. Myocardial protection for neonates and infants. Thorac Cardiovasc Surg 1998;46(suppl):288–291.
Teoh KH, Christakis GT, Weisel RD, Fremes SE, Mickle DAG, Romaschin AD, et al. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia (hot shot). J Thorac Cardiovasc Surg 1986;91:888–895.
Weisel RD, Mickle DAG, Finkle CD, Tumiati LC, Madonik M, Ivanov J, et al. Myocardila free-radical injury after cardioplegia. Circulation 1989;80(suppl III):III-14–III-18.
Ludmer PL, Wright RF, Arnold JM, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administrated by an intracoronary infusion technique. Circulation 1986;73:130–137.
Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N, Obara H, et al. The effect of phosphodiesterase inhibitors on human neutrophil function. Crit Care Med 2000;28:1001–1005.
Sill JC, Bertha B, Berger I, Uhl C, Nugent M, Folts J. Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone. Circulation 1997;96:1647–1653.
Chen CC, Matsuda H, Sawa Y, Kaneko M, Sakagoshi N, Nishimura M, et al. Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury. Ann Thorac Surg 1991;52:495–499.
Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955–958.
Chanani NK, Cowan DB, Takeuchi K, Poutias DN, Garcia LM, del Nido PJ, et al. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling. Circulation 2002;106:I-284–I-289.
Kobayashi T, Sugawara Y, Ohkubo T, Imamura H, Makuuchi M. Effect of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol 2002;37:31–38.
Tabata T, Sugawara T, Matsumura Y. The effect of the specific type III phosphodiesterase inhibitor, olprinone, on ischemia-reperfusion injury after lung transplantation in rats. Isyoku 2005;40:273–278.
Mizutani A, Murakami K, Okajima K, Kira S, Mizutani S, Kudo K, et al. Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock 2005;24:281–287.
Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors. Circulation 2001;104:705–710.
Besirli K, Burhani SM, Arslan C, Suzer O, Sayin AG. Effect of combining phosphodiesterase III inhibitors with St Thomas hospital’s solution used as transplantation preservative solution in isolated rat hearts. Transpl Proc 2006;38:1253–1258.
Shimada Y, Yamamoto F, Yamamoto H, Newling R. Is the use of catecholamine before ischemic arrest safe? Jpn J Thorac Cardiovasc Surg 1999;47:299–312.
Ikeda Y, Lee M, Yoshino F, Uchino H. Free radical scavenging activity of phosphodiesterase III inhibitor olprinone. J Jpn Soc Intensive Care Med 2006;13:57–59.
Sagawa K, Maughan L, Suga H. Cardiac contraction and the pressure-volume relationship. New York: Oxford University Press; 1988.
Gilbert JC, Glantz SA. Determinant of left ventricular filling and of the diastolic pressure-volume relation. Circ Res 1989;64:827–852.
Ishikawa H, Jin MB, Ogata T, Taniguchi M, Suzuki T, Shimamura T, et al. Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers. Transplantation 2002;73:1041–1048.
Satoh H, Endoh M. Effect of new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-[imidazo (1,2-a) pyridine-6-yl]-3-pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle. Jpn J Pharmacol 1990;52:215–224.
Kaneko K, Tadano K, Nakajima K, Sano Y, Yuzuriha T, Motoji N, et al. Studies on the metabolic fate of loprinone hydrochloride. 1. Blood level, distribution, metabolism, excretion after a single intravenous administration on rats. Yakubutsudoutai 1994;9:149–162.
Van der Zypp A, Rechtman M, Majewski H. The role of cyclic nucleotide metabolism and calcium in the relaxation produced by amrinone in rat aorta. Gen Pharmacol 2000;34:245–253.
Dhaliwai H, Kirshenbaum LA, Randhawa AK, Singal PK. Correlation between antioxidant changes during hypoxia and recovery on reoxygenation. Am J Physiol 1991;261:H632–H638.
Sato T, Saito T, Saegusa N, Nakaya H. Mitochondrial C2+-activated K+ channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 2005;111:198–203.
Kloner RA, Przklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion. Circulation 1987;76:1135–1145.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kinouchi, K., Morita, K., Ko, Y. et al. Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor. Gen Thorac Cardiovasc Surg 60, 73–81 (2012). https://doi.org/10.1007/s11748-011-0810-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-011-0810-4